{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "transcribes",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ00166",
      "entity_text" : "MHC-II",
      "entity_type" : "gene"
    },
    "hypothesis_information" : false,
    "context" : {
      "TissueType" : [ "tissuelist:TS-0971" ],
      "CellLine" : [ "cellosaurus:CVCL_E508" ],
      "Cellular_component" : [ "go:GO:0018995" ],
      "Organ" : [ "uberon:UBERON:0002405" ],
      "Species" : [ "taxonomy:9606" ],
      "CellType" : [ "cl:CL:0000034" ]
    }
  },
  "verbose_text" : "Treatment of cells with the receptor TKI ruxolitinib (and to a lesser extent IFN-gamma) enhanced the expression of MHC-II on CML stem / progenitor cells and was associated with an increase in CML cell immunogenicity (enhanced CD4 + T cell proliferation) in a JAK dependent manner.",
  "reading_complete" : "2020-08-04T10:01:13Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T09:57:39Z",
  "trigger" : "expression",
  "evidence" : [ "expression of MHC-II" ],
  "pmc_id" : "5402174",
  "score" : 0
}